Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse Model
- PDF / 1,953,974 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 43 Downloads / 185 Views
ORIGINAL ARTICLE
Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse Model J. B. Delaye 1 & D. Lanznaster 2 & C. Veyrat-Durebex 1,2 & A. Fontaine 3 & G. Bacle 2,4 & A. Lefevre 2 & R. Hergesheimer 2 & J. C. Lecron 5 & P. Vourc’h 1,2 & C. R. Andres 1,2 & F. Maillot 2,6 & P. Corcia 2,7 & P. Emond 2,8 & H. Blasco 1,2 Accepted: 15 September 2020 # The American Society for Experimental NeuroTherapeutics, Inc. 2020
Abstract In amyotrophic lateral sclerosis (ALS), motor neuron degeneration occurs simultaneously with systemic metabolic dysfunction and neuro-inflammation. The fibroblast growth factor 21 (FGF21) plays an important role in the regulation of both phenomena and is a major hormone of energetic homeostasis. In this study, we aimed to determine the relevance of FGF21 pathway stimulation in a male mouse model of ALS (mutated SOD1-G93A mice) by using a pharmacological agonist of FGF21, R1Mab1. Mice (SOD1-WT and mutant SOD1-G93A) were treated with R1Mab1 or vehicle. Longitudinal data about clinical status (motor function, body weight) and biological parameters (including hormonal, immunological, and metabolomics profiles) were collected from the first symptoms to euthanasia at week 20. Multivariate models were performed to identify the main parameters associated with R1Mab1 treatment and to link them with clinical status, and metabolic pathways involving the discriminant metabolites were also determined. A beneficial clinical effect of R1Mab1 was revealed on slow rotarod (p = 0.032), despite a significant decrease in body weight of ALS mice (p < 0.001). We observed a decrease in serum TNF-α, MCP-1, and insulin levels (p = 0.0059, p = 0.003, and p = 0.01, respectively). At 16 weeks, metabolomics analyses revealed a clear discrimination (CV-ANOVA = 0.0086) according to the treatment and the most discriminant pathways, including sphingolipid metabolism, butanoate metabolism, pantothenate and CoA biosynthesis, and the metabolism of amino acids like tyrosine, arginine, proline, glycine, serine, alanine, aspartate, and glutamate. Mice treated with R1Mab1 had mildly higher performance on slow rotarod despite a decrease on body weight and could be linked with the anti-inflammatory effect of R1Mab1. These results indicate that FGF21 pathway is an interesting target in ALS, with a slight improvement in motor function combined with metabolic and anti-inflammatory effects. Keywords Amyotrophic lateral sclerosis . Metabolomics . FGF21 . R1Mab1 . Therapeutic antibody . SODG93A
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13311-020-00933-3) contains supplementary material, which is available to authorized users. * J. B. Delaye [email protected] 1
2
3
4
Service de chirurgie orthopédique, Centre Hospitalier Régional Universitaire de Tours, hôpital Trousseau, 37044 Tours, France
5
Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 2 Bd Tonnellé, 37044 Tours C
Data Loading...
